================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                       PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

         DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): JULY 13, 2005

                               TRANSGENOMIC, INC.
             (Exact name of registrant as specified in its charter)

               Delaware                                 000-30975
         (State of Formation)                   (Commission File Number)

                                    911789357
                      (IRS Employer Identification Number)

          12325 Emmet Street
               Omaha, NE                                  68164
  (Address of principal executive offices)              (Zip Code)

                                 (402) 452-5400
              (Registrants' telephone number, including area code)

                                 Not applicable
          (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[ ]  Written communications pursuant to Rule 425 under the Securities
     Act (17 CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange
     Act (17 CFR 240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e(c))

================================================================================



ITEM 8.01  OTHER EVENTS.

        On July 13, 2005, the Company issued a press release detailing comments
made at its annual meeting of shareholders, including projections of neutral to
positive operating cash flow by year end, and BioSystems revenue growth
approaching 20% year over year. A copy of the press release is filed herewith as
Item 9.01 and is incorporated herein by reference.

ITEM 9.01  FINANCIAL STATEMENTS AND EXHIBITS.

Exhibits

(99)    Press Release, dated July 13, 2005, detailing comments made at its
annual meeting of shareholders, including projections of neutral to positive
operating cash flow by year end, and BioSystems revenue growth approaching 20%
year over year.

                                        2


                                   SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                                    TRANSGENOMIC, INC.

                                                    By /s/ Mitchell L. Murphy
                                                       -------------------------
                                                       Mitchell L. Murphy
                                                       VP, Secretary & Treasurer

July 15, 2005

                                        3